Related Experiment Video
Updated: Jun 5, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials
N Clumeck1, P Cahn, J-M Molina
1Division of Infectious Diseases, Saint-Pierre University Hospital, Brussels, Belgium. nathan_clumeck@stpierre-bru.be
Abstract:
The objective of this subanalysis of the Phase III DUET trials was to examine virological response to an etravirine-containing regimen in patients harbouring virus fully sensitive to etravirine. Full etravirine sensitivity was defined as fold change in 50% effective concentration (FC) ≤3 or weighted genotypic score ≤2. At Week 48 in the etravirine group, 74% of patients with etravirine FC ≤3 and 77% with etravirine genotypic score ≤2 had viral load <50 HIV-1 RNA copies/mL, versus 48% and 46%, respectively, in the placebo group (P < 0.0001). Response rates increased with baseline phenotypic sensitivity score, but were consistently higher with etravirine (56-82%) than placebo (2-72%). Similar observations were made in patients harbouring virus with full etravirine and darunavir sensitivity. Our findings support current recommendations to include three active agents in treatment-experienced patients' regimens.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Retroviruses
Retrovirus Life Cycles
Inhibitors Of Virion Release
Subviral Agents
Bioavailability Study Design: Single Versus Multiple Dose Studies

